The vpr gene of human immunodeficiency virus type 1 (HIV-1) encodes a 15-kDa virion-associated protein that functions as a regulator of cellular processes linked to the HIV life cycle. We report the interaction of a 41-kDa cytosolic viral protein R interacting protein 1 (Rip-i) 
activated receptor complex. Vpr complementation of a vpr mutant virus was also mimicked by GR-II-stimulating steroids. Vpr and GR-II actions were inhibited by mifepristone, a GR-II pathway inhibitor. Together these data directly link the activity of the vpr gene product to the glucocorticoid steroid pathway and provide a biochemical mechanism for the cellular and viral activity of Vpr, as well as suggest that a unique class of antivirals, which includes mifepristone (RU486), may influence HIV-1 replication.
Human immunodeficiency virus (HIV)-1, HIV-2, and simian immunodeficiency virus contain, in addition to the canonical gag/pol/env genes, additional small open reading frames encoding gene products, including the 96-amino acid 15-kDa virion-associated HIV-1 Vpr gene product. The conservation of the vpr open reading frame in primate lentiviral evolution suggests that vpr is critical to viral function. The incorporation of vpr into virions (1, 2) , as well as its cellular colocalization with gag (3) (4) (5) , has led to speculation that vpr performs a structural role in the virus particle. However, vpr-deletion mutant viruses produce virions that appear normal in electron micrographs (6) , and vpr-deletion mutant viruses remain infectious with somewhat lower replication kinetics in many CD4+ T-cell lines (7) (8) (9) (10) . It has been suggested that delivery of Vpr into cells by virus could increase cellular permissiveness to early events in virus replication (11) .
Expression of the vpr gene of HIV-1 is sufficient to induce growth arrest and cellular differentiation (11) , and HIV-1 replication in macrophages can be inhibited by vpr antisense deoxyribonucleotides (12) . vpr-deletion mutants are poorly infectious in myeloid lines in vitro (13, 14) , indicating an important function for vpr in infection of this lineage. In trans extracellular Vpr protein increases virus replication in T lymphocytes and monocyte/macrophages in vitro (15) , although the effects on monocytes/macrophages were clearly greater. nef-, vpr-mutant simian immunodeficiency virus replicated poorly in nonhuman primates (16) . Purified Vpr protein isolated from HIV+ patient serum reactivates HIV-1 replication in nonproductively infected cells (17) .
Transfection studies have shown that Vpr is a weak transactivator of the HIV long terminal repeat and several other heterologous viral promoters, including human T-lympho-
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tropic virus 1, Epstein-Barr virus, and cytomegalovirus (10).
These observations and the fact that vpr is packaged into virions suggest that vpr may function as an activator of viral mRNA transcription in the pretranscriptional tat-independent stage (18 
MATERIALS AND METHODS
Cell Culture and Virus Preparation. The U937 human promyelocytic cell line and the human embryonal rhabdomyosarcoma (RD) cell line were from the American Type Culture Collection and maintained as described (11, 17) . Viruses were prepared as described (15, 17) .
Ligand Blot. About 3 x 106 cells were washed in phosphatebuffered saline (PBS) and lysed in lysis buffer [150 mM NaCl/50 mM Tris, pH 8.0/0.5% (vol/vol) Triton X-100/ protease inhibitors], as described (19) . Cell lysates were incubated on ice for 10 min with frequent mixing, then centrifuged at 12,000 x g for 6 min. The soluble (a crude preparation consisting of the suspension of both cytoplasmic, as well as cytoplasmic membrane and plasma membrane, fractions) and the insoluble fractions (organelle plus nuclear fraction) were run on SDS/12% PAGE and transferred to poly(vinylidene difluoride) membranes (Millipore) (20) . Membranes were blocked by incubation with 5% nonfat dry milk dissolved in Tris buffer saline (TBS)/0.05% Tween 20 and washed extensively. These membranes were incubated with either purified Vpr protein ("50 ng/ml) or an irrelevant protein (bovine serum albumin, 50 ng/ml). Membranes were washed and detected with anti-Vpr antiserum 808, followed by 125I-labeled protein G (NEN). The membranes were blotted, air-dried, and exposed to film for 12 hr at -80°C. (15, 17, 21) .
Crosslinking. Fractions containing proteins were resuspended in PBS. This material was exposed to either the noncleavable crosslinking agent disuccinimidyl suberate (DSS) or the reversible crosslinking agent 3,3'-dithiobis(sulfosuccinimidylpropionate) (DTSSP; Pierce), as described (19) .
Expression and Purification of Recombinant HIV-1 Vpr. Expression of Vpr in insect cells has been described (15, 17) . For purification, Triton X-100 at 0.05% (vol/vol; final concentration) was added to the baculovirus supernatants that were passed over a rabbit anti-Vpr column (17) . After being washed, the columns were eluted as follows. Three bed volumes of the preelution buffer 10 mM phosphate buffer/0.05% Triton X-100, pH 8.0, were passed through the column, followed by the elution buffer 10 mM triethanolamine/0.05% Triton X-100, pH 11.5. The eluate was collected and neutralized with 1/20th vol of 1 M sodium phosphate buffer, pH 6.8/0.05% Triton X-100.
Immunoprecipitation of GR Complexes. U937 cells were stimulated with the indicated agents and exposed to crosslinking agents (DSS or DTSSP) and subsequently lysed. The lysates were centrifuged at 12,000 x g for 10 min, and immediately used for immunoprecipitation (19) using a specific mouse anti-human GR reagent (Affinity BioReagents, Jersey City, NJ) covalently coupled to protein G-agarose beads (GIBCO/ BRL) using dimethyl pimelimidate 2HCl (Pierce) (20) . Alternatively, U937 cells were lysed and then stimulated with the indicated agents. The stimulated lysates were then exposed to crosslinking reagents, and these preparations were used in immunoprecipitation analysis.
RESULTS

Identification of Vpr Cellular Binding Proteins in Cell
Lysates. We investigated the interaction of Vpr with cellular proteins that might couple Vpr to intracellular signaling pathways. R interacting protein 1 (Rip-1) was detected by using either recombinant (data not shown) or virally derived Vpr protein (Fig. 1A) . We detected a 41-kDa protein (Rip-1) from the soluble fractions but not in the Triton X-100-insoluble fraction. Rip-1 and Vpr coeluted from a Vpr-specific immunoaffinity column (Fig. 1B) . Next, a Vpr-CNBr-activated Sepharose column loaded with the Triton X-100-soluble fraction of RD cell lysates was eluted to yield a single major protein (>95% purity). This protein corresponded in size to Rip-1 and reacted with Vpr in a ligand blot system similarly to the protein found in total cell lysate ( Fig. 1 C) . Furthermore, Rip-1 and Vpr could be reversibly crosslinked to a 58-kDa heterodimeric complex that reacted with the Vpr-specific antibody in immunoblot or ligand blots (Fig. 1D) We tested the effects of steroid hormones on Rip-1 translocation. Although minor loading differences were seen in a particular assay, the gels were run a minimum of three times with similar results. Vpr induced Rip-1 translocation (Fig. 3A and B, lanes 1 and 2). Neither control supernatants (Fig. 3 A  and B, lanes 3 and 4) , PBS (Fig. 3A, lanes 11 and 12) , nor PMA induced Rip-I translocation (Fig. 3A, lanes 5 and 6) . Both dexamethasone (at 10-6 M) (Fig. 3A and B, lanes 7 and 8) and hydrocortisone (10-6 M), which demonstrated almost complete Rip-1 translocation (Fig. 3B , lanes 5 and 6) (activators of GR-II pathway), but not all-trans-retinoic acid (Fig. 3A, (lanes 3 and 4) , PMA (lanes 5 and 6), dexamethasone (lanes 7 and 8) , all-trans-retinoic acid (lanes 9 and 10), or PBS (lanes 11 and 12) . The odd-numbered lanes contain the Triton X-100 crude soluble fraction, and the even-numbered lanes contain the insoluble cytosolic and nuclear fractions. (B) Triton X-100 lysates of U937 cells previously exposed to either Vpr protein (lanes 1 and 2) , control supernatants (lanes 3 and 4), hydrocortisone (lanes 5 and 6), dexamethasone (lanes 7 and 8), hydrocortisone and mifepristone (lanes 9 and 10), or Vpr protein and mifepristone (lanes 11 and 12) . These gels were probed with Vpr protein and a Vpr antibody (as for Fig. 1 ). The high-molecular-weight background spot was not reproducible in multiple experiments.
effect of glucocorticosteroids on infection of U937 cells with vpr virus. NL43Avpr viruses were rendered replication competent by complementation in trans with either Vpr protein, dexamethasone, or hydrocortisone (Fig. 4) [24] [25] [26] 32) . The nuclear translocation of Rip-1 induced by dexamethasone (data not shown) and hydrocortisone was blocked by mifepristone treatment (Fig. 3B) . Similarly, Vpr-induced translocation of Rip-1 was also blocked by mifepristone (Fig. 3B) . We examined mifepristone effects on viral replication. The levels of virus produced by infected cells exposed to mifepristone were -70% lower than in the untreated cultures. Mifepristone also inhibited the enhancement in virus production seen on addition of Vpr protein or the two steroids ("80-90% inhibition). Furthermore, the transcomplementation observed for the NL43Avpr-infected U937 cells by Vpr protein was abolished by mifepristone treatment (Fig. 4 C and G) . The mifepristone inhibitory effects were dose responsive (Fig. 4 D Fig. 5 shows that the fractions that contain GR also have Vpr and Rip-1. In addition, the fractions that were crosslinked with DSS show that GR, as well as Vpr and Rip-1, is involved in a high-molecular-weight complex. These data demonstrate that Rip-1 is a part of the GR complex after Vpr-induced activation. Fig. 1 (B (27, 29, 30) . The activated GR complex represents a less negatively charged DNA-binding protein complex (31) . The activated receptor complex shuttles to the nuclear compartment (33, 34) , where it binds their specific nucleic acid target sequences (27, 28) , inducing specific transcriptional activation. Interestingly, binding sites for GR are found in the HIV long terminal repeat (4, 35, 36) . One such glucocortocoid response element site is the TGTTCT GR target sequence, homologous to that which has been defined for the mouse mammary tumor virus long terminal repeat (37) . We have observed that Vpr affects transcriptional activation of the HIV long terminal repeat through its ability to directly activate the GR-II pathway (unpublished work). Such a transcriptional regulatory mechanism might serve to unify the observed Vpr effects on cell differentiation and proliferation (11) , latency (17) , and replication (15) .
DISCUSSION
The possibility that Rip-1 represents another form of or another member of the GR-II family does not exclude the alternative in which Vpr and/or Rip-1 form a part of the GR transcription complex. It is conceivable that Vpr alters Rip-1 such that it binds to the complex to promote receptor transformation and the subsequent nuclear translocation. A role for Vpr in translocation of the HIV-1 preintegration complex has been recently suggested (38) . Vpr through its association with Rip-1 could form the basis of a cellular shuttle for the other members of the complex through its cooperation with nucleocapsid protein. Epstein-Barr virus expression in Daudi cells (40) , as well as reverse the dexamethasone-induced inhibition of growth in a human cervical-carcinoma cell line (41) . We observed that mifepristone could inhibit both the Vpr-induced GR translocation event, as well as the Vpr-induced enhancement of viral replication. Collectively these data allow speculation into Vpr biology as it relates to the HIV life cycle and viral pathogenesis. Linking Vpr to the GR-mediated transcriptional pathway could establish a link between a viral protein and several pathologies observed in AIDS patients. Glucocorticoids have widespread immunosuppressive effects and are reported to interact with both the NF-KB and FK506 pathways (43, 44) , which may have relevance for HIV biology. Glucocorticoids have been reported to induce apoptosis in thymocytes and T cells. Viralinduced apoptosis of lymphocyte precursor populations is implicated in the T-cell depletion, which is a hallmark of HIV infection (for review, see ref. 4) . These data are also interesting in view of the several observed pathological features present in some HIV-1-positive patients and also in some patients exhibiting glucocorticoid steroid toxicity. These common symptoms include muscle wasting and susceptibility to fungal infections (45) . The GR-II pathway could be exploited in an autocrine fashion by HIV through the action of the vpr gene product. Inhibitors of this specific pathway, which include mifepristone (RU486) [11f3-(4-dimethylaminophenyl)-1703-hydroxy-17a-(propyl-1-ynyl)-4,9-dien-3-oneI among others, may have relevance for the clinical management of HIV infection. Collectively, these studies provide a unified basis for understanding many seemingly disparate activities of Vpr, including nuclear translocation, increased viral replication, cellular differentiation, and inhibition of cell proliferation-as well as providing a context for analyzing the observed transcriptional activational properties of this HIV accessory gene.
